Stay updated on Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial page.

Latest updates to the Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page has been updated to reflect new dates in February 2025, replacing previous dates from August 2024.SummaryDifference0.8%
- Check23 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check30 days agoNo Change Detected
- Check37 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check44 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.4%
- Check59 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check66 days agoChange DetectedThe type of intervention has been updated from version v2.13.3 to v2.14.0.SummaryDifference0.4%
Stay in the know with updates to Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial page.